

#13/K.T.
5/22
S-PPL
I.D.S.
ISPH-0588

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of
Rosanne M. Crooke

Appln. No. 09/918,026

Filed: July 30, 2001

For: ANTISENSE MODULATION OF ACYL
COA CHOLESTEROL ACYLTRANSFERASE-2
EXPRESSION

) Group Art Unit: 1635

) Examiner: Gibbs, Terra C

) HAND DELIVERED

) March 31, 2003

RECEIVED
TECH CENTER 1600/2900
03 MAR 31 PM 3:57

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action on the merits. Therefore, a fee of \$180.00 is due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

04/10/2003 KBENDY 00000009 09916026
01 FC:1806 180.00 02

REMARKS

Listed below are documents that were cited in the International Search Report dated December 17, 2002 in the corresponding International Patent Application No. PCT/US02/22746. A copy of the Report is enclosed, together with copies of the documents.

(1) Document WO 99/67368 that is listed on the search report was cited by the examiner in the Notice of References Cited accompanying the Office Action dated November 19, 2002 in the present application.

(2) Japanese patent publication JP0217286(A), for which an English language abstract is also provided as (BQ), relates to an acyl-CoA:cholesterol acyltransferase inhibitor containing at least one of the following:

(a) a pyrimidine selected from thymine, uracil or cytosine, and/or a purine selected from adenine, guanine or hypoxanthine;

(b) a nucleoside selected from adenosine, guanosine, cytidine uridine, thymidine or inosine having one of the above-noted pyrimidine or purine bases; and/or

(c) a nucleotide selected from adenylic acid, guanylic acid, cytidylic acid, uridylic acid, thymidylic acid or inosinic acid having one of the above-noted pyrimidine or purine bases.

When blended with additives, the compound is useful in treating hypercholesterolemia or atherosclerosis.

(3) BUHMAN-Resistance to diet-induced hypercholesterolemia and Gallstone formation in ACAT2-deficient mice, Nature Medicine, Vol. 6, No. 12, December 2000

Listed below is a document cited in the International Search Report mailed on December 23, 2002 in a related International Patent Application No. PCT/US02/22696. A copy of the Report is enclosed, together with a copy of the document.

(1) TAYLOR, Antisense Oligonucleotides: A Systematic High-throughput Approach to Target Validation and Gene Function Determination, DDT, Vol. 4, No. 12, December 1999

Listed below is a previously filed, co-pending, U.S. patent application. This application and the present application are commonly owned. A copy of the following application is enclosed.

(1) U.S. Patent Application No. 09/920,394, filed August 1, 2001.

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200